IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice

DOI: 10.1164/ajrccm.160.6.9901043
American Journal of Respiratory and Critical Care Medicine, 1999, 160, 2040-7.

#	Paper	IF	Citations
113	IL-10, but not IL-4, suppresses infection-stimulated bone resorption in vivo. **2000**, 165, 3626-30		148
112	Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice. *American Journal of Respiratory and Critical Care Medicine*, **2000**, 161, 271-9	10.2	91
111	A CD-1 mouse model of infection with Staphylococcus aureus: Influence of gender on infection with MRSA and MSSA isolates. **2000**, 46, 920-926		16
110	Transfer of heme oxygenase 1 cDNA by a replication-deficient adenovirus enhances interleukin 10 production from alveolar macrophages that attenuates lipopolysaccharide-induced acute lung injury in mice. **2001**, 12, 967-79		112
109	Cytokine- and microbially induced sleep responses of interleukin-10 deficient mice. **2001**, 280, R1806-14		51
108	Interleukin-10. **2001**, 31, 269-273		
107	Susceptibility to cytomegalovirus infection may be dependent on the cytokine response to the virus. **2001**, 49, 434-41		14
106	Inflammation and cystic fibrosis pulmonary disease. **2001**, 21, 593-603		12
105	Reduced Smad3 protein expression and altered transforming growth factor-beta1-mediated signaling in cystic fibrosis epithelial cells. **2001**, 25, 732-8		38
104	Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. **2002**, 303, 45-51		43
103	Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. **2002**, 277, 35466-74		122
102	Pseudomonas aeruginosa activates human mast cells to induce neutrophil transendothelial migration via mast cell-derived IL-1 alpha and beta. **2002**, 169, 4522-30		71
101	Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. *American Journal of Respiratory and Critical Care Medicine*, **2002**, 165, 1176-81	10.2	65
100	Murine models of CF airway infection and inflammation. **2002**, 70, 495-515		7
99	Functional IL-10 deficiency in the lung of cystic fibrosis (cftr(-/-)) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar macrophages. **2002**, 168, 1903-10		62
98	Cystic Fibrosis Methods and Protocols. **2002**,		1
97	Inflammation bronchique pr□oce dans la mucoviscidose. **2002**, 196, 29-35		7

96	Persistent infections and immunity in cystic fibrosis. **2002**, 7, d442-57		20
95	Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. **2002**, 54, 1409-23		64
94	Influence of gender and interleukin-10 deficiency on the inflammatory response during lung infection with Pseudomonas aeruginosa in mice. **2002**, 107, 297-305		42
93	Symposium summaries S8.2–13.3. **2002**, 34, 127-152		
92	The role of inflammation in the pathophysiology of CF lung disease. **2002**, 23, 5-27		180
91	Use of modulators of airways inflammation in patients with CF. **2002**, 23, 29-39		3
90	Monitoring inflammation in CF. Cytokines. **2002**, 23, 41-57		34
89	Severe Infections Caused by Pseudomonas Aeruginosa. *Perspectives on Critical Care Infectious Diseases*, **2003**,		11
88	Cystic fibrosis. **2003**, 361, 681-9		800
87	Regulation of innate immune response by Stat proteins during septic peritonitis. **2003**, 1255, 7-14		
86	Imaging lung inflammation in a murine model of Pseudomonas infection: a positron emission tomography study. **2003**, 29, 45-57		21
85	Decreased neutrophil apoptosis in tracheal fluids of preterm infants at risk of chronic lung disease. **2003**, 88, F245-9		20
84	Pseudomonas aeruginosa alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. **2003**, 52, 731-740		61
83	Experimental Pseudomonas aeruginosa keratitis in interleukin-10 gene knockout mice. **2003**, 71, 1328-36		30
82	IL-10 controls Aspergillus fumigatus- and Pseudomonas aeruginosa-specific T-cell response in cystic fibrosis. *Pediatric Research*, **2003**, 53, 313-9	3.2	20
81	Current and future treatment of cystic fibrosis. **2003**, 428-450		
80	Bacterial quorum sensing signalling molecules as immune modulators. **2003**, 201-222		2
79	Lung inflammation as a therapeutic target in cystic fibrosis. **2004**, 31, 377-81		86

78	Isoprenoid-mediated control of SMAD3 expression in a cultured model of cystic fibrosis epithelial cells. **2004**, 31, 234-40	26
77	Pseudomonas aeruginosa-induced neutrophilic lung inflammation is attenuated by adenovirus-mediated transfer of the heme oxygenase 1 cDNA in mice. **2004**, 15, 273-85	23
76	Quantitative cytokine gene expression in CF airway. **2004**, 37, 393-9	52
75	De la colonie microbienne à l'infection chez l'homme : le cas de Pseudomonas aeruginosa, importance thérapeutique. **2004**, 6, 241-248	
74	Gene delivery systems--gene therapy vectors for cystic fibrosis. **2004**, 3 Suppl 2, 203-12	23
73	Chronic Pseudomonas aeruginosa infection in cystic fibrosis airway disease: metabolic changes that unravel novel drug targets. **2004**, 2, 611-23	26
72	Effects of CFTR, interleukin-10, and Pseudomonas aeruginosa on gene expression profiles in a CF bronchial epithelial cell Line. **2004**, 10, 562-73	43
71	Mucoviscidose. **2004**, 1, 1-14	
70	Antiinflammatory therapies for cystic fibrosis: past, present, and future. **2005**, 25, 555-73	33
69	Anti-Inflammatory Agents. **2005**, 34, 187-194	
68	[Cystic fibrosis modifying genes]. **2005**, 59, 395-404	3
67	Bacterial induction of TNF-alpha converting enzyme expression and IL-6 receptor alpha shedding regulates airway inflammatory signaling. **2005**, 175, 1930-6	59
66	Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent. **2005**, 4, 255-73	27
65	Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. **2006**, 7, 134	77
64	Enhanced IgE allergic response to Aspergillus fumigatus in CFTR-/- mice. **2006**, 86, 130-40	19
63	Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?. **2006**, 374, 65-77	18
62	Respiratory syncytial virus infection in a murine model of cystic fibrosis. **2006**, 78, 651-8	35
61	Impact of IL-10 on diaphragmatic cytokine expression and contractility during Pseudomonas Infection. **2007**, 36, 504-12	27

60	[Treatment of airway inflammation in cystic fibrosis]. **2007**, 14, 1350-5	1
59	Inflammation and anti-inflammatory therapies for cystic fibrosis. **2007**, 28, 331-46	78
58	What have we learned from mouse models for cystic fibrosis?. **2007**, 7, 407-17	18
57	Pseudomonas aeruginosa and the host pulmonary immune response. **2007**, 1, 121-37	5
56	Sputum biomarkers of inflammation in cystic fibrosis lung disease. **2007**, 4, 406-17	122
55	Decreased interleukin-10 in tracheal aspirates from preterm infants developing chronic lung disease. **2002**, 91, 1194-9	33
54	Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling. **2008** , 34, 146-62	86
53	Anti-inflammatory therapies for cystic fibrosis-related lung disease. **2008**, 35, 135-53	30
52	Mutual modulation between interleukin-10 and interleukin-6 induced by Rhodococcus aurantiacus infection in mice. **2008**, 10, 1450-8	4
51	Modulation of cystic fibrosis lung disease by variants in interleukin-8. **2008**, 9, 501-8	53
50	Increased weight loss with reduced viral replication in interleukin-10 knock-out mice infected with murine cytomegalovirus. **2008**, 151, 155-64	33
49	Association of interleukin-10 gene haplotypes with Pseudomonas aeruginosa airway colonization in cystic fibrosis. **2008**, 7, 329-332	8
48	Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies. **2008**, 42, 389-412	64
47	Interleukin-10 is an essential modulator of mucoid metaplasia in a mouse otitis media model. **2008**, 117, 630-6	12
46	Hyperinflammation in airways of cystic fibrosis patients: what's new?. **2008**, 8, 359-63	26
45	Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/- mice. **2009**, 40, 295-304	146
44	The pros and cons of immunomodulatory IL-10 gene therapy with recombinant AAV in a Cftr-/--dependent allergy mouse model. **2009**, 16, 172-83	15
43	How useful are cystic fibrosis mouse models?. **2009**, 6, 35-41	11

42	Evaluation of interleukin-10 production in Pseudomonas aeruginosa induced acute pyelonephritis. **2009**, 2, 136-40	5
41	Development and function of IL-10 IFN-gamma-secreting CD4(+) T cells. **2009**, 86, 1305-10	28
40	Inflammation, Hyperinflammation & Cystic Fibrosis Lung Disease A Paradigm Shift?. **2009**, 5, 136-148	
39	New Genetic and Pharmacological Treatments for Cystic Fibrosis. **2009**, 5, 8-27	2
38	Defining human mesenchymal stem cell efficacy in vivo. **2010**, 7, 51	58
37	IL-10 delivery by AAV5 vector attenuates inflammation in mice with Pseudomonas pneumonia. **2010**, 17, 567-76	29
36	Human mesenchymal stem cells suppress chronic airway inflammation in the murine ovalbumin asthma model. **2010**, 299, L760-70	150
35	Induction of Chronic Pneumonia in Normal Mice by Klebsiella pneumoniae. **2012**, 102-110	
34	Absence of the cystic fibrosis transmembrane regulator (Cftr) from myeloid-derived cells slows resolution of inflammation and infection. **2012**, 92, 1111-22	88
33	Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde?. **2012**, 323, 115-27	105
32	Recent insights into microbial triggers of interleukin-10 production in the host and the impact on infectious disease pathogenesis. **2012**, 64, 295-313	62
31	The relationship of systemic inflammation to prior hospitalization in adult patients with cystic fibrosis. **2012**, 12, 3	18
30	Antibiotic and anti-inflammatory therapies for cystic fibrosis. **2013**, 3, a009779	40
29	Thrombospondin-1 triggers macrophage IL-10 production and promotes resolution of experimental lung injury. **2014**, 7, 440-8	42
28	Chondroitin-6-sulfate attenuates inflammatory responses in murine macrophages via suppression of NF-B nuclear translocation. **2014**, 10, 2684-92	39
27	Symposium Summaries. **2015**, 50 Suppl 41, S108-92	1
26	IL-10/HMOX1 signaling modulates cochlear inflammation via negative regulation of MCP-1/CCL2 expression in cochlear fibrocytes. **2015**, 194, 3953-61	18
25	Animals devoid of pulmonary system as infection models in the study of lung bacterial pathogens. **2015**, 6, 38	31

24	Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. **2015**, 14, 419-30		276
23	A chronic rhinosinusitis-derived isolate of Pseudomonas aeruginosa induces acute and pervasive effects on the murine upper airway microbiome and host immune response. **2016**, 6, 1229-1237		5
22	Opposing roles of IL-10 in acute bacterial infection. **2016**, 32, 17-30		42
21	Role of Neutrophils in Cystic Fibrosis Lung Disease. **2017**,		2
20	Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases. **2018**, 15, 312-323		16
19	Expanding the Current Knowledge About the Role of Interleukin-10 to Major Concerning Bacteria. **2018**, 9, 2047		15
18	Recombinant IFN-□for Postseptic Acute Lung Injury-What's the Mechanism?. **2018**, 59, 1-2		4
17	HDAC6 depletion improves cystic fibrosis mouse airway responses to bacterial challenge. **2019**, 9, 10282		8
16	Lights and Shadows in the Use of Mesenchymal Stem Cells in Lung Inflammation, a Poorly Investigated Topic in Cystic Fibrosis. **2019**, 9,		9
15	Inflammasome activation by Pseudomonas aeruginosa's ExlA pore-forming toxin is detrimental for the host. **2020**, 22, e13251		3
14	The role of IL-10 in immune responses against Pseudomonas aeruginosa during acute lung infection. **2021**, 383, 1123-1133		1
13	Effects of edpetiline from Fritillaria on inflammation and oxidative stress induced by LPS stimulation in RAW264.7 macrophages. *Acta Biochimica Et Biophysica Sinica*, **2021**, 53, 229-237	2.8	0
12	Lung Protection vs. Infection Resolution: Interleukin 10 Suspected of Double-Dealing in COVID-19. *Frontiers in Immunology*, **2021**, 12, 602130	8.4	9
11	Cystic Fibrosis Lung Disease in the Aging Population. *Frontiers in Pharmacology*, **2021**, 12, 601438	5.6	3
10	Donor-defined mesenchymal stem cell antimicrobial potency against nontuberculous mycobacterium. *Stem Cells Translational Medicine*, **2021**, 10, 1202-1216	6.9	4
9	Interleukin-10. **2022**, 295-302		
8	Cell based therapy aides in infection and inflammation resolution in the murine model of cystic fibrosis lung disease. *Stem Cell Discovery*, **2013**, 03, 139-153	0.5	25
7	New Perspectives on Prevention and Management of Pseudomonas Aeruginosa Infections. *Perspectives on Critical Care Infectious Diseases*, **2003**, 183-199		

6	IL-10 Controls Aspergillus fumigatus??? and Pseudomonas aeruginosa???Specific T-Cell Response in Cystic Fibrosis. *Pediatric Research*, **2003**, 53, 313-319	3.2	15
5	Pseudomonas aeruginosa Biofilm Infections in Cystic Fibrosis. **2005**, 155-169		
4	Quantitative microscopy in murine models of lung inflammation. **2011**, 33, 245-52		5
3	The Role of MIF and IL-10 as Molecular Yin-Yang in the Modulation of the Host Immune Microenvironment During Infections: African Trypanosome Infections as a Paradigm.. *Frontiers in Immunology*, **2022**, 13, 865395	8.4	0
2	BtpB inhibits innate inflammatory responses in goat alveolar macrophages through the TLR/NF-B pathway and NLRP3 inflammasome during Brucella infection.. *Microbial Pathogenesis*, **2022**, 105536	3.8	1
1	Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the irst in Cystic Fibrosis Phase I Clinical Trial (CEASE-CF). **2023**, 16, 220		0